JVJuan Esteban Velez-Hernandez

Juan Esteban Velez-Hernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Esteban Velez-Hernandez has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disseminated Cutaneous, Osteoarticular, and Tubulointerstitial Sporotrichosis in an Immunosenescent and Diabetic Host: A Case Report

    by Juan Esteban Velez-Hernandez, Natalia Giraldo, Erika Andrea Sánchez-Cifuentes, María del Pilar Jiménez-Alzate, Fernando Lopez-Urbano

    Introduction: Disseminated sporotrichosis is an uncommon presentation of this infectious disease, primarily observed in immunocompromised patients. Here, we present a case of disseminated sporotrichosis occurring in an immunosenescent patient. Case presentation: An 81‐year‐old man presented to our clinic with skin ulcers in the scalp, back, right arm, and both legs, knee arthritis, and acute kidney injury. After skin biopsy and synovial fluid analysis, the diagnosis of disseminated sporotrichosis was made using fungal culture and in‐house PCR. The only factor that favored immunocompromise was immunosenescence. Conclusion: This case of disseminated sporotrichosis highlights its rare occurrence in a patient with controlled diabetes and immunosenescence. Advanced diagnostics confirmed Sporothrix schenckii as the causative agent, and itraconazole treatment led to significant improvement.


  • Open Access

    Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

    by Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H. Mouhieddine, Juan Esteban Velez-Hernandez, Katherine Engles, Joshua A. Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, et al.

    B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay in the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion after infusion has been shown to inform depth and duration of response (DoR), but measuring this process remains investigational. This multicenter study describes the kinetics and prognostic impact of absolute lymphocyte count (ALC) in the first 15 days after CAR-T infusion in 156 patients with relapsed MM treated with the BCMA-targeting agents ciltacabtagene autoleucel and idecabtagene vicleucel. Patients with higher maximum ALC (ALCmax) had better depth of response, progression-free survival (PFS), and DoR. Patients with ALCmax >1.0 × 103/μL had a superior PFS (30.5 months vs 6 months; P < .001) compared with those with ≤1.0 × 103/μL, whereas patients with ALCmax ≤0.5 × 103/μL represent a high-risk group with early disease progression and short PFS (hazard ratio, 3.4; 95% confidence interval, 2-5.8; P < .001). In multivariate analysis, ALCmax >1.0 × 103/μL and nonparaskeletal extramedullary disease were the only independent predictors of PFS and DoR after accounting for international staging systemic staging, age, CAR-T product, high-risk cytogenetics, and the number of previous lines. Moreover, our flow cytometry data suggest that ALC is a surrogate for BCMA CAR-T expansion and can be used as an accessible prognostic marker. We report, to our knowledge, for the first time the association of ALC after BCMA CAR-T infusion with clinical outcomes and its utility in predicting response in patients with R/R MM.


  • Open Access

    Impact of Vancomycin trough levels monitoring on uncomplicated methilcillin-resistant Staphylococcus aureus bacteremia in chronic kidney disease on hemodialysis, retrospective cohort

    by Julian Felipe Ramirez-Osorio, Juan Esteban Velez-Hernandez, Nathalia Fernandez-Castaño, David Felipe Rojas-Hernandez, Fabian Jaimes

    Background: CKD patients on hemodialysis (HD) with Staphylococcus aureus (SA) bacteremia present high morbidity, mortality and increased risk of MRSA. Vancomycin is the antibiotic of choice in these cases, it has a narrow therapeutic margin and inadequate dosage generates a risk of toxicity, therefore, the recommendation is to dosage it through serum levels. Methods: This is a retrospective cohort study in 3 hospitals of third level of complexity in the city of Medellin in which there were differences in the measurement and implementation of vancomycin25 dosage based on trough levels (VL) in patients with chronic kidney disease on hemodialysis (CKD- HD) with uncomplicated bacteremia based infection by methilcillin-resistant Staphyloccocus aureus (MRSA). The primary outcome was the composite of hospital mortality, clinical response (fever, hemodynamic instability and altered consciousness), complications associated with bacteremia, or bacteriological response failure (positive cultures at first week follow-up) at 7 days. The composite variables were analyzed individually as secondary outcomes. Results: The main unadjusted outcome (OR 1.3, CI 0.6 - 2.7) and adjusted for age, Charlson index, loading dose, initial dose, dosing frequency and MIC to vancomycin (OR 1.2, CI 0.5 - 2.7). Regarding adjusted secondary outcomes: clinical response (OR 1.4 CI 0.3 - 5.8), death (OR 1.3 CI 0.3 - 4.6) and complications (OR 0.9, CI 0.37 - 2.2). Conclusions: We conclude that the measurement of trough levels in patients with HD-CKD does not modify the composite outcome. The main limitation is the sample size and type of study, randomized control trials may be required to confirm the results presented.


  • Open Access

    Impact of Vancomycin trough levels monitoring on uncomplicated methilcillin-resistant Staphylococcus aureus bacteremia in chronic kidney disease on hemodialysis, retrospective cohort

    by Julian Felipe Ramirez Osorio, Juan Esteban Velez-Hernandez, Nathalia Fernández Castaño, David Felipe Rojas Hernandez, Fabian Jaimes Barragan

    Background CKD patients on hemodialysis (HD) with Staphylococcus aureus (SA) bacteremia present high morbidity, mortality and increased risk of MRSA. Vancomycin is the antibiotic of choice in these cases, it has a narrow therapeutic margin and inadequate narrow therapeutic margin and inadequate dosage generates a risk of toxicity, therefore, they recommend that its dosage be guided through measurement of serum levels. Methods This is a retrospective cohort study in 3 hospitals of third level of complexity in the city of Medellin in which there were differences in the measurement and implementation of vancomycin25 dosage based on trough levels (VL) in patients with chronic kidney disease on hemodialysis (CKD- HD) with uncomplicated bacteremia based infection by methilcillin-resistant Staphyloccocus aureus (MRSA). The primary outcome was the composite of hospital mortality, clinical response (fever, hemodynamic instability and altered consciousness), complications associated with bacteremia or bacteriological response failure (positive cultures at first week follow-up) at 7 days, and the composite variables were analyzed individually as secondary outcomes. Results The main unadjusted outcome (OR 1.3, CI 0.6–2.7) and adjusted for age, Charlson index, loading dose, initial dose, dosing frequency and MIC to vancomycin (OR 1.2, CI 0.5–2.7). Regarding adjusted secondary outcomes: clinical response (OR 1.4 CI 0.3–5.8), death (OR 1.3 CI 0.3–4.6) and complications (OR 0.9, CI 0.37–2.2). Conclusions We conclude that the measurement of trough levels in patients with HD-CKD does not modify the composite outcome. The main limitation is the sample size and type of study, so that preferably randomized studies are required to confirm the results presented.

  • Quality of life in early-onset Alzheimer’s disease due to a PSEN1-E280A mutation

    by Daniel Vasquez, Melissa Sierra Castrillón, Manuela Gomez Vega, Clara Gomez Henck, David Aguillon, Elkin Garcia-Cifuentes, Alberto Jaramillo-Jimenez, Juan Esteban Velez, Lucia Madrigal, Francisco Lopera

    Purpose The present study aims to explore the association between the quality of life (QoL) score and the clinical and sociodemographic variables in patients with the PSEN1-E280A mutation. We also seek to evaluate the differences between the QoL reported by the patients (P-QoL) and the scores reported by the caregivers (C-QoL). Methods An analysis of 75 patients with the PSEN1-E280A mutation with mild cognitive impairment and dementia was performed. We used the Quality of Life in Alzheimer Disease (QoL-AD) survey to evaluate QoL as an outcome and evaluated its association with sociodemographic, lifestyle, clinical, and past medical history variables. Results The largest difference in the median of the QoL-AD score was in those who needed help to eat, those with moderate or severe dementia, those classified as frail or pre-frail, those with moderate social risk, and those with depression. Also, C-QoL was lower than the P-QoL, and the QoL-AD of individuals with severe dementia was lower than for milder forms of the disease. Not needing help to eat, not having a stressful situation in the past 3 months, and the years of education were positively correlated with QoL-AD in the linear model. Conclusion As studies in similar populations with AD, factors with more impact on QoL are those related to loss of functionality and independence. These factors are also associated with variables related to the current literature with the burden of the disease for the caregivers.


  • Open Access

    Nutritional Assessment in Patients with Early-Onset Autosomal Dominant Alzheimer's Disease Due to PSEN1- E280A Genetic Variant: A Cross-Sectional Study

    by M. Gómez-Vega, E. Garcia-Cifuentes, D. Aguillon, J.E. Velez, A. Jaramillo-Jimenez, D. Vasquez, C. Gómez-Henck, C. Andrés Tobon, G.C. Deossa Restrepo, F. Lopera

    Weight loss and malnutrition are frequent findings in late-onset and sporadic presentations of Alzheimer’s Disease (AD). However, less is known about nutritional status in Early-Onset Autosomal Dominant AD (EO-ADAD). To analyze the association between nutritional status and other clinical and sociodemographic characteristics in individuals with a genetic form of EO-ADAD. Cross-sectional study with 75 non-institutionalized participants from a cohort of Autosomal Dominant AD (13 with mild cognitive impairment and 61 with dementia, ages from 38 to 67 years) underwent a structured clinical assessment with emphasis on nutritional status. Primary outcome was nutritional status and it was measured using the Mini Nutritional Assessment (MNA). Patients were categorized according to MNA total score, as undernourished (MNA ≤23.5) and well-nourished (MNA ≥ 24). Sociodemographic and clinical variables identified as potential predictors or confounders of nutritional status were also collected. Undernourishment by MNA was present in 57.3% of the sample. Forty-two percent of participants had abnormal BMI values considered lower than 18.5 or higher than 24.9 kg/m2. Total BMI values were similar in well and undernourished patients (median 24.2 IQR 3.59 and median 23.9 IQR 4.42, respectively, p=0.476). When comparing well and undernourished groups, we found statistically significant differences for variables: severity of dementia (p=0.034), frailty (p=0.001), multimorbidity (p=0.035) and, polymedication (p=0.045). Neither adjusted logistic regression nor the Poisson regression showed that any clinical or sociodemographic variables explained undernourishment. Undernourishment was a frequent finding in our sample of EO-ADAD, especially in later stages of the disease. Patients with polymedication, multimorbidity, frailty and severe dementia show differences in their nutritional status with a tendency to be more frequently undernourished. Further studies with larger sample sizes are needed to establish this association.


  • Open Access

    Prevenir la demencia: un reto para la salud pública en Colombia

    by Elkin Garcia-Cifuentes, Alberto Jaramillo-Jimenez, David Aguillon, Manuela Gómez-Vega, Juan Esteban Velez-Hernandez, Carlos Cano Gutiérrez, Francisco Lopera

    El Sitio oficial de la Asociación Colombiana de Neurología